Acknowledgements
Alexia, Cancer
CANCER
We thank all the platforms and services at Curie involved in the study: Cytometry, Experimental Pathology, and Clinical Immunology. Celine Cousin for technical contribution on FACS staining. High-throughput sequencing was performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10 INBS-09-08 (France Génomique Consortium) from the Agence Nationale de la Recherche (“Investissements d’Avenir” program), by the ITMO-Cancer Aviesan (Plan Cancer III) and by the SiRIC-Curie program (SiRIC Grant INCa-DGOS- 4654). We thank Alexia Savignoni for input on the trial design. We thank Pierre-Emmanuel Bonté for his advice on biostatistical analyses. We thank Nina Jehanno and Christophe Le Tourneau for their support with patient care. We thank Charlotte Martinat and Constance Lamy for their help accessing archived material. We thank Sabrina Leclercq, Marie-Emmanuelle Legrier, Jennifer Dieppedale, and Anne-Sophie Plissonnier for support with data acquisition, monitoring, and management of trial procedures. This work was supported by the following grants to ER: Bristol-Myers Squibb (BMS) funded the clinical trial and the associated translation research. BMS had no role in study design, data collection and analysis, or manuscript writing. CIC IGR-Curie 1428; ANR-10-IDEX-0001-02 PSL; ANR-11-LABX-53 0043. M.R. is supported by the Interface INSERM program. E.T. was supported by a postdoctoral fellowship abroad from the AIRC (2018/2020-54 number: 20934).